Maria Martin-Grau, at the University of Valencia, Spain is selected for the 2022 Novelties in Biomarkers award

UPPSALA, Sweden, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) is proud to announce the 2022 winner of the young researchers’ award, Novelties in Biomarkers,Maria Martin-Grau at the University of Valencia, Spain at the Biomarkers of the Future conference in Paris, France.

Novelties in Biomarkers is an annual award established in 2019 by Olink Proteomics with the purpose of encouraging and motivating young scientists in the use of biomarker discovery in their research.

This year’s theme Biomarkers in 2023: Emerging applications attracted over 30 abstract submissions, with participants representing countries from five continents (Africa, Asia, Europe, North America, South America). The abstracts cover more than ten different fields including Infectious diseases, Neurology, Metabolism, Cardiology, Oncology, Hepatology. The scientific committee judging the award comprised Professor Alexandre Mebazaa, Chair of the meeting (Paris, France), Professor Antoni Bayes-Genis (Barcelona, Spain), Doctor Jane-Lise Samuel, chair of the Jury (Paris, France), Professor Jelena Čelutkienė (Vilnius, Lithuania) and Professor Camille Gobeaux (Paris, France).

“Proteomics is still a relatively new and rapidly growing field of research. However, the sharp rise in demand for proteomics has created a global shortage of skilled researchers within the field. Universities alone cannot supply the competence that the world is demanding,” said Professor Alexandre Mebazaa, vice-dean for international affairs at the faculty of health department of the Université de Paris, Head of anesthesia and critical care of the Saint Louis-Lariboisière - Fernand Widal University Hospitals and Director of Inserm-MASCOT research group. “Innovative institutional and industry initiatives are essential to encourage young researchers to explore the new frontiers of proteomics and translate these for clinical use. The Novelties in Biomarkers award is a pioneering award that sets an example for this entire field of research, and the huge interest in the award is a testament to that.”

The Biomarker of the Future conference brings together international key opinion leaders along with young fellows, senior researchers, and industry partners, all focusing on biomarker discovery and research. The meeting is directed to the application of high-throughput targeted proteomics as a key tool to understand biology and pathophysiology, as well as identify protein biomarkers for early diagnosis and progression of major complex diseases.

“To learn proteomics today, young researchers from different continents need more and equal opportunities to interact with senior scientists. The Novelties in Biomarkers award is Olink’s response to address the skills gap and secure future competence within the discipline. As a company it is important for Olink to have its ear on the ground and celebrate some of the very best young researchers in the field.” said Henk Mouthaan, Vice President Salesand Marketing EMEA, Olink.

The conference is supported by Olink Proteomics. The institutional partners are Université de Paris, Institut de science cardiovasculaire, Institut national de la santé et de la recherche médicale (Inserm), Investigation Network Initiative-Cardiovascular and Renal Clinical Trialists (INI-CRCT), GREAT Association (Global research on acute conditions team).

More details are available at: Biomarkers of the Future

Investor contact
Jan Medina, CFA
VP Investor Relations & Capital Markets
jan.medina@olink.com

Media contact
Andrea Prander
Corporate Communications Manager
Mobile: +46 768 775 275
andrea.prander@olink.com

About Olink
Olink Holding AB (publ) (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major pharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.

Forward-Looking Statements
This release may contain forward-looking statements within the meaning of applicable securities laws, including the U.S. Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Olink’s strategy, business plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs as of the date hereof and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those related to Olink’s business, operations, supply chain, strategy, goals and anticipated timelines, including for the delivery of Olink Explore 3072 and the expansion of the Explore platform, competition, and other risks identified in the section entitled “Risk Factors” in Olink’s Registration Statement on Form F-1, as amended (File No. 333-253818) filed with the U.S. Securities and Exchange Commission (SEC) and in the other filings, reports, and documents Olink files with the SEC from time to time. Olink expressly disclaims any obligation to update any forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.